click here
 
   
 
Jump Search | Advanced Search
HOME PAGE FOR THE WORLD'S BUSINESS LEADERS
 
Home > Breaking News


Get quotes


REUTERS
UK says U.S. FDA evaluating data on GSK's Seroxat
Reuters, 06.10.03, 5:59 AM ET


ADVERTISEMENT

E-Mail Alerts  
Topics
  European Union  
Enter E-Mail Address:                 FAQ  |  Privacy Policy
eLibrary @ Forbes.com more > 
Research topics related to this story in the eLibrary news and magazine archives.
European Union   
 
LONDON, June 10 (Reuters) - Britain's drug regulatory agency said on Tuesday the U.S. Food and Drug Administration was evaluating data on GlaxoSmithKline Plc's <GSK.L> antidepressant Seroxat after the UK warned it should not be given to children.

Medicines and Healthcare products Regulatory Authority (MHRA) officials, addressing a news conference, said Europe's CPMP expert committee on medicines had also been alerted.

The MHRA recommended Seroxat should not be used to treat depression in people under 18 after new data showed an increase in the rate of self-harm and suicidal tendencies in those taking the drug in this age group.

Copyright 2003, Reuters News Service





Send comments

E-mail story


 


 
Ad Information       Forbes.com Wireless       Reprints / Permissions       Subscriber Services      
© 2003 Forbes.comô      All Rights Reserved       Privacy Statement       Terms, Conditions and Notices
 

 
    
Market data provided by Reuters. Disclaimer
Stock quotes are delayed at least 15 minutes for Nasdaq, at least 20 minutes for NYSE/AMEX.
U.S. indexes are delayed at least 15 minutes with the exception of S&P 500 which is real-time.
Forbes 40 Index powered by Telemet.
News may include latest headlines from Reuters.